Cyclosporine in the Treatment of Palmoplantar Pustulosis

Reitamo, Sakari; Erkko, Pekka; Remitz, Anita; Lauerma, Antti; Montonen, Outi; Harjula, K.

doi:10.1001/archderm.1993.01680310043006

Cited by 56 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results showed complete remission in 8.3% of patients, remission in 41.7%, improvement in 22.9%, and treatment ineffectiveness in 20.8%, with an overall effectiveness rate of 50%. These results are consistent with relevant results in the literature [5–7] and they confirm that cyclosporine is an effective treatment for PPP.…”

Section: Discussionsupporting

confidence: 93%

Effects of Cyclosporine on Palmoplantar Pustulosis and Serum Expression of IL-17, IL-23, and TNF-α

Jin

Chen

Mou

et al. 2019

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction This study aimed to investigate the effects of cyclosporine on palmoplantar pustulosis (PPP) and serum expression of IL-17, IL-23, and TNF-α. Methods Patients with PPP ( n = 48) were recruited and treated with cyclosporine alone. The Palmoplantar Pustulosis Area and Severity Index score was obtained, and ELISA was employed to detect the serum IL-17, IL-23, and TNF-α expression before treatment and after 8 weeks of treatment. Results Complete remission was achieved in 16.7% of the patients, remission in 45.8%, an improvement in 31.3%, and the treatment was ineffective in 6.25%, yielding an overall effectiveness of 62.5%. Adverse effects included hypertension ( n = 6), frequent urination and enuresis nocturna ( n = 6), gastrointestinal discomfort ( n = 6), hypertrichosis ( n = 3), and increased creatinine ( n = 1). While serum IL-17, IL-23, and TNF-α concentrations were reduced after 8 weeks of treatment, the reductions were greatest for IL-23 and TNF-α, whereas the reduction in IL-17 was not significant. Conclusion Cyclosporine is a safe and effective treatment for PPP with few adverse effects, which might be related to the regulation of IL-23 and TNF-α.

show abstract

Section: Discussionsupporting

confidence: 93%